Organovo Holdings Inc (ONVO)

$0.67

-0.04

(-5.87%)

Market is closed - opens 7 PM, 12 Jul 2024

Insights on Organovo Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 5.0K → 29.0K (in $), with an average increase of 82.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -7.45M → -3.04M (in $), with an average increase of 28.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 80.7% return, outperforming this stock by 143.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 222.8% return, outperforming this stock by 314.7%

Performance

  • $0.65
    $0.73
    $0.67
    downward going graph

    2.99%

    Downside

    Day's Volatility :10.96%

    Upside

    8.22%

    downward going graph
  • $0.65
    $2.05
    $0.67
    downward going graph

    2.99%

    Downside

    52 Weeks Volatility :68.29%

    Upside

    67.32%

    downward going graph

Returns

PeriodOrganovo Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
-33.37%
6.1%
0.0%
6 Months
-36.51%
4.9%
0.0%
1 Year
-62.82%
13.6%
0.0%
3 Years
-91.9%
14.3%
-22.5%

Highlights

Market Capitalization
9.7M
Book Value
$0.36
Earnings Per Share (EPS)
-1.6
PEG Ratio
0.0
Wall Street Target Price
8.55
Profit Margin
0.0%
Operating Margin TTM
-10675.86%
Return On Assets TTM
-70.73%
Return On Equity TTM
-155.0%
Revenue TTM
109.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-82.1%
Gross Profit TTM
-8.5M
EBITDA
-14.8M
Diluted Eps TTM
-1.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.74
EPS Estimate Next Year
-1.37
EPS Estimate Current Quarter
-0.42
EPS Estimate Next Quarter
-0.38

Analyst Recommendation

Hold
    0
    0%Buy
    57%Hold
    42%Sell
Based on 7 Wall street analysts offering stock ratings for Organovo Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
4
4
4
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 1176.12%

Current $0.67
Target $8.55

Technicals Summary

Sell

Neutral

Buy

Organovo Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Organovo Holdings Inc
Organovo Holdings Inc
-26.84%
-36.51%
-62.82%
-91.9%
-93.46%
Moderna, Inc.
Moderna, Inc.
-16.86%
15.92%
-2.46%
-48.68%
764.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.12%
15.76%
50.37%
88.19%
269.25%
Novo Nordisk A/s
Novo Nordisk A/s
-2.42%
30.45%
80.67%
222.84%
488.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.43%
13.55%
42.21%
148.12%
179.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Organovo Holdings Inc
Organovo Holdings Inc
NA
NA
0.0
-1.74
-1.55
-0.71
NA
0.36
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Organovo Holdings Inc
Organovo Holdings Inc
Hold
$9.7M
-93.46%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
764.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
269.25%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
488.09%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
179.95%
31.94
39.46%

Institutional Holdings

  • Vanguard Group Inc

    2.72%
  • BlackRock Inc

    1.09%
  • Renaissance Technologies Corp

    0.75%
  • Geode Capital Management, LLC

    0.58%
  • Morgan Stanley - Brokerage Accounts

    0.32%
  • State Street Corporation

    0.21%

Company Information

organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.

Organization
Organovo Holdings Inc
Employees
12
CEO
Mr. Keith E. Murphy
Industry
Health Technology

FAQs